CC-223, a mTOR kinase inhibitor, has been found to be effective in inducing the apoptosis and reducing the proliferation of tumor cells. It is still under Phase I/II clinical trial by Celgene Corporation. IC50: 16 nM.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | mTOR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.